Adjuvant hormonal therapy in premenopausal women with breast cancer.

as older (nonanthracycline/taxane-based) chemotherapy regimens, however the trials assessed did not have tamoxifen in both arms and indeed in the trials of LHRH agonists plus tamoxifen versus chemotherapy, the endocrine combination did not significantly decrease rate of recurrence or death, despite a favorable trend to do so.[ 25 , 28 ] Chemotherapy induced amenorrhea The indirect endocrine effect of CIA in premenopausal women with ER-positive tumors has been associated with the improved treatment outcome on retrospective analysis.[ 30 , 31 , 32 , 33 ] Rates of CIA are dependent on a number of factors, includi

also in 1,053 other papers

l women with ER+ breast cancer.[ 28 ] Consistent with results from the 2005 EBCTCG overview, LHRH agonists when used as the only systemic adjuvant treatment, showed a 28% ( P = 0.08) reduction in the risk of recurrence and 18% ( P = 0.49) reduction in the risk of death.[ 28 ] However, these results did not reach statistical significance, possibly due to small patient numbers ( n = 338).[ 29 ] Furthermore, adding OFS to tamoxifen did not significantly decrease recurrence (HR 0.85) or death after recurrence (HR 0.84).

also in 77,393 other papers

The clinical relevance of BMI may be significant, given a third of premenopausal patients with breast cancer are overweight.[ 41 ] In the tamoxifen and exemestane trial (TEXT), 2672 premenopausal women were randomized to OFS plus tamoxifen or exemestane for 5 years.

also in 8,502 other papers